NeoGenomics, Inc. (NEO)
| Market Cap | 1.08B -7.9% |
| Revenue (ttm) | 727.33M +10.1% |
| Net Income | -108.03M |
| EPS | -0.84 |
| Shares Out | 130.14M |
| PE Ratio | n/a |
| Forward PE | 53.48 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,253,555 |
| Open | 7.89 |
| Previous Close | 7.91 |
| Day's Range | 7.84 - 8.33 |
| 52-Week Range | 4.72 - 13.74 |
| Beta | 1.71 |
| Analysts | Buy |
| Price Target | 11.14 (+34.38%) |
| Earnings Date | Apr 28, 2026 |
About NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and ge... [Read more]
Financial Performance
In 2025, NeoGenomics's revenue was $727.33 million, an increase of 10.11% compared to the previous year's $660.57 million. Losses were -$108.03 million, 37.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for NEO stock is "Buy." The 12-month stock price target is $11.14, which is an increase of 34.38% from the latest price.
News
NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' oncology testing portfolio is now available through Epic Aura.
NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present eight scientific posters and one oral presentation at the AACR Annual Meeting 2026 in San Diego, Calif., April 17–22, 2026.
NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first qu...
NeoGenomics' PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' PanTracer™ LBx test has received coverage from the Centers for Medicare & Medicaid Services' Molecular Diagnostics Services Program.
NeoGenomics Transcript: Leerink Global Healthcare Conference 2026
Leadership highlighted improved alignment between commercial and R&D teams, driving innovation and operational efficiency. Financial guidance projects mid-single-digit growth in volume and AUP for 2026, with margin expansion as new products mature. Strong early uptake of PanTracer and RaDaR ST supports a positive outlook.
NeoGenomics Transcript: TD Cowen 46th Annual Health Care Conference
Management highlighted pivotal product launches in therapy selection and MRD, robust NGS-driven growth, and a strategic shift to higher-margin contracts. Sales force expansion and operational improvements are expected to drive margin gains, with a bullish outlook for 2027 and beyond.
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the launch of RaDaR® ST, its circulating tumor DNA assay for detecting molecular residual disease.
NeoGenomics to Participate in Upcoming Investor Conferences
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the TD Cowen 46th Annual Health Care Conference in Boston and the Leerink Global Healthcare Conference in Miami.
NeoGenomics Earnings Call Transcript: Q4 2025
Q4 and full-year results showed double-digit revenue growth, driven by strong clinical and NGS performance, with new product launches and strategic focus on high-value testing. 2026 guidance anticipates continued revenue and margin expansion, supported by new product adoption and operational efficiencies.
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its fourth-quarter and full-year results for the period ended December 31, 2025.
NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launches PanTracer Pro, designed to help clinicians navigate complex molecular testing and support informed solid tumor decisions.
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Feb. 17, 2026.
NeoGenomics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Exclusive focus on oncology diagnostics and community care has driven double-digit revenue growth, with NGS and MRD markets as key expansion areas. New product launches, operational efficiencies, and targeted investments are expected to sustain above-market growth into 2026 and beyond.
NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company's Chief Financial Officer.
NeoGenomics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of John P. “Jack” Kenny to its Board of Directors.
NeoGenomics Announces that Natera Has Voluntarily Withdrawn its Appeal in Ongoing RaDaR Patent Litigation
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced that Natera has voluntarily withdrawn its appeal in ongoing RaDaR patent litigation.
NeoGenomics to Present New ctDNA Research at SABCS 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present data on its RaDaR 1.0 assay for molecular residual disease detection at the 2025 San Antonio Breast Cancer Symposium.
NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present new data at ASH on how comprehensive genomic profiling supports diagnosis and treatment decisions in myeloid malignancies.
NeoGenomics Transcript: Piper Sandler 37th Annual Healthcare Conference
Clinical revenue and NGS growth are outpacing the market, driven by sales force investments, new product launches, and strategic acquisitions. RaDaR ST and PanTracer LBX are set to drive further gains in 2026, while operational efficiencies and AI adoption are expected to enhance margins.
NeoGenomics Transcript: Stephens Annual Investment Conference
Strong clinical growth was driven by NGS and high-value test adoption, with MRD re-entry and new product launches set to fuel future expansion. Operational improvements and targeted sales strategies are expected to boost margins and regional penetration, while pharma headwinds are anticipated to ease by 2027.
NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present research at ISLB 2025 showing high concordance between its RaDaR ST and RaDaR 1.0 MRD assays, plus four additional posters.
NeoGenomics Earnings Call Transcript: Q3 2025
Q3 2025 saw record clinical volumes and 12% revenue growth, driven by strong NGS and MRD performance, while non-clinical revenue declined. Guidance for 2025 was reiterated, with continued investment in R&D and operational efficiencies, and major product launches expected to drive growth in 2026.
NeoGenomics Reports Third Quarter 2025 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its third-quarter results for the period ended September 30, 2025.
NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will share at ESMO 2025 how its RaDaR ST MRD assay can support pharmaceutical partners across oncology research and clinical trials.